EBV 阳性原发性肺淋巴上皮瘤样癌对 PD-L1 阻断的反应 - Suppr

Suppr

超能文献

EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.

作者信息

Narayanan Anand, Knollmann Friedrich D, Walby Julie Ann S, Lim Steffany, Gandara David R, Riess Jonathan W

机构信息

UC Davis School of Medicine, Sacramento, CA.

Department of Radiology, UC Davis School of Medicine, Sacramento, CA.

出版信息

Clin Lung Cancer. 2019 May;20(3):e238-e241. doi: 10.1016/j.cllc.2018.12.015. Epub 2018 Dec 27.

DOI:10.1016/j.cllc.2018.12.015

PMID:30679078

Abstract

摘要

相似文献

EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.EBV 阳性原发性肺淋巴上皮瘤样癌对 PD-L1 阻断的反应

Clin Lung Cancer. 2019 May;20(3):e238-e241. doi: 10.1016/j.cllc.2018.12.015. Epub 2018 Dec 27.

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.阿替利珠单抗用于 PD-L1 选择的 NSCLC 患者的一线治疗。

N Engl J Med. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346.

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.IMpassion132 三期临床试验：阿替利珠单抗联合化疗治疗早期复发转移性三阴性乳腺癌。

Future Oncol. 2019 Jun;15(17):1951-1961. doi: 10.2217/fon-2019-0059. Epub 2019 Apr 12.

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?在联合化疗的情况下，哪种免疫疗法是晚期鳞状非小细胞肺癌的最佳选择：抗 PD-1 还是抗 PD-L1？

J Immunother Cancer. 2018 Dec 3;6(1):135. doi: 10.1186/s40425-018-0427-6.

First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.一线铂类化疗与局部晚期或转移性肺淋巴上皮瘤样癌的生存结局。

Lung Cancer. 2019 Nov;137:100-107. doi: 10.1016/j.lungcan.2019.09.007. Epub 2019 Sep 12.

Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.免疫检查点调节剂、细胞毒性 T 淋巴细胞抗原 4 和程序性死亡配体 1 在 Epstein-Barr 病毒相关鼻咽癌中的表达。

Appl Immunohistochem Mol Morphol. 2021 Jul 1;29(6):401-408. doi: 10.1097/PAI.0000000000000903.

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.血清来源的外泌体 PD-L1 表达预测抗 PD-1 反应和非小细胞肺癌患者。

Sci Rep. 2021 Apr 9;11(1):7830. doi: 10.1038/s41598-021-87575-3.

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.免疫治疗之外的治疗选择：野生型肺腺癌患者的德尔菲共识。

Clin Transl Oncol. 2020 May;22(5):759-771. doi: 10.1007/s12094-019-02191-y. Epub 2019 Jul 31.

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.抗 PD-1/PD-L1 免疫疗法在 KRAS 突变型非小细胞肺癌中的优越疗效与炎症表型和增加的免疫原性相关。

Cancer Lett. 2020 Feb 1;470:95-105. doi: 10.1016/j.canlet.2019.10.027. Epub 2019 Oct 20.

Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.活检样本的形态学、免疫和遗传学特征与非鳞状非小细胞肺癌患者接受派姆单抗疗效的相关性。

J Cancer Res Clin Oncol. 2021 Apr;147(4):1227-1237. doi: 10.1007/s00432-020-03413-5. Epub 2020 Sep 30.

引用本文的文献

Case Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features.病例报告：爱泼斯坦-巴尔病毒阴性的淋巴上皮瘤样胆管癌：一种值得进一步探索的罕见肿瘤。1例具有独特基因组和临床特征的病例报告。

Front Oncol. 2025 Aug 4;15:1620328. doi: 10.3389/fonc.2025.1620328. eCollection 2025.

EpsteinBarr virusassociated lymphoepitheliomalike intrahepatic cholangiocarcinoma: A report of 3 cases and literature review.Epstein-Barr 病毒相关的淋巴上皮样肝内胆管癌：3 例报告及文献复习。

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Feb 28;49(2):319-330. doi: 10.11817/j.issn.1672-7347.2024.230298.

Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival.原发性肺淋巴上皮瘤样癌：应用卡瑞利珠单抗和安罗替尼延长生存时间的 1 例报告。

Anticancer Agents Med Chem. 2024;24(12):954-960. doi: 10.2174/0118715206294031240404071838.

Pathogenesis and therapeutic implications of EBV-associated epithelial cancers.EB病毒相关上皮性癌的发病机制及治疗意义

Front Oncol. 2023 Oct 2;13:1202117. doi: 10.3389/fonc.2023.1202117. eCollection 2023.

Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma.抗 PD-1 抗体，一种晚期化疗耐药性肺淋巴上皮瘤样癌的新型治疗选择。

Front Immunol. 2022 Dec 6;13:1001414. doi: 10.3389/fimmu.2022.1001414. eCollection 2022.

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.PD-1/PD-L1 联合 LAG3 与转移性原发性肺淋巴上皮瘤样癌中免疫检查点抑制剂的临床活性相关。

Front Immunol. 2022 Oct 3;13:951817. doi: 10.3389/fimmu.2022.951817. eCollection 2022.

PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.PD-1 抑制剂联合铂类化疗（PBC）或 PBC 单独用于局部晚期或转移性肺淋巴上皮瘤样癌的一线治疗。

Front Immunol. 2022 Sep 29;13:1015444. doi: 10.3389/fimmu.2022.1015444. eCollection 2022.

Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study.多原发部位淋巴上皮样癌的临床特征和治疗结局：一项基于人群、多中心、真实世界研究。

BMC Pulm Med. 2022 Sep 22;22(1):360. doi: 10.1186/s12890-022-02097-6.

Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study.晚期原发性肺淋巴上皮瘤样癌的抗血管生成治疗：一项回顾性多中心研究。

J Cancer Res Clin Oncol. 2023 Mar;149(3):1185-1193. doi: 10.1007/s00432-022-03935-0. Epub 2022 Apr 4.

The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers.爱泼斯坦-巴尔病毒对免疫检查点的影响：淋巴增生性疾病和癌症的证据及后果

Biomolecules. 2022 Mar 4;12(3):397. doi: 10.3390/biom12030397.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验